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Abstract 
Although somatic mutations are the main contributor to cancer, underlying germline alterations may 
increase the risk of cancer, mold the somatic alteration landscape and cooperate with acquired mutations 
to promote the tumor onset and/or maintenance. Therefore, both tumor genome and germline sequence 
data have to be analyzed to have a more complete picture of the overall genetic foundation of the disease. 
To reinforce such notion we quantitatively assess the bias of restricting the analysis to somatic mutation 
data using mutational data from well-known cancer genes which displays both types of alterations, 
inherited and somatically acquired mutations.  
Introduction 
In spite that germline susceptibility variants underlying advanced cancers generally evade to be clinically 
actionable, these inherited alterations are proving to be more relevant than anticipated (Ngeow & Eng, 
2016). For instance, in a survey of 1566 patients nearly 16% of pathogenic variants linked to an inherited 
human disease were found in germline variants of 187 overlapping genes (Prasad et al., 2015). Moreover, 
using 466 DNAs from healthy tissues homozygous deletions (HD) totaling ~23 Mb and spanning  1% of 
protein-coding genes have been classified as germline HD (Bignell et al., 2010). Interestingly, loss of 
heterozygosity (LOH) for the wild-type allele of some tumor suppressor genes frequently associates with 
inherited germline mutations supporting the so called two hit hypothesis (Knudson, 1971; Nomoto et al., 
2000; Saito et al., 2000).  For instance, LOH for the wild-type allele have been found in 100% and 76% of 
cases with germline BRCA1 and BRCA2 truncations in ovarian cancer (Kanchi et al., 2014). Finally, 
cooperation between germline mutations and somatically acquired alterations within the same or 
different genes has been recently described in several tumor localizations (Lu et al., 2015). Altogether, 
these evidences implicate germline mutations/deletions as underlying active alterations modulating the 
risk to get cancer, influencing the tumor genome stability and cooperating with somatically acquired 
mutations to promote the cancer onset and/or maintenance.  
Although somatic and germline genomes can be ascertained from studies that perform sequencing of 
tumor and normal-matched samples, most of the state-of-the-art multidimensional cancer genomics 
analysis tools (e.g. CBioPortal, UCSC Cancer Genome Browser) and driver gene prediction methods (e.g. 
IntoGen, MutSigCV) use filtered data; therefore restricting the analysis to somatically acquired mutations. 
While somatic alterations are the main contributor to cancer, the above mentioned evidences suggest 
inherited germline mutations imparts susceptibility and frequently shapes the acquired somatic alteration 
landscape (Lu et al., 2015).  Therefore, both tumor genome and germline sequence data have to be 
analyzed to provide a more integral picture of the overall genetic contribution to disease (Kanchi et al., 
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2014). Here we quantitatively assess the impact of restricting the analysis to somatic mutation data in the 
study of the genetic contribution to cancer. 
Methods 
We assume here that at least one of the variants considered in the study drives cancer development with 
detectable penetrance. When dealing with penetrance of genotypes epistasis and correlations are 
considered by construction. We disregard genotyping errors for the sake of simplicity. 
Briefly, an individual with genotype 𝑔 has a probability 𝐹𝑔 to be drawn from a population (patient + non 
patient), and the chance (penetrance) an individual with genotype 𝑔 have cancer is denoted 𝑝𝑔. 
Consequently, the probability of drawing a cancer individual with genotype 𝑐 from the population is 𝑝𝑐𝐹𝑐, 
and the probability of drawing a genotype 𝑐 individual from patients is 𝑝𝑐𝐹𝑐/ ∑ 𝑝𝑔𝐹𝑔𝑔 , where the 
denominator is the probability of drawing a cancer individual from the population, and 𝑔 run within the 
possible genotypes.  
The expected number 𝑛𝑐 of individual with genotype 𝑐 in a patient sample of size 𝑛 is  
⟨𝑛𝑐⟩~𝑛
𝑝𝑐𝐹𝑐
∑ 𝑝𝑔𝐹𝑔𝑔
 
The penetrance 𝑝𝑐 of this alteration can be approximate by 
⟨𝑝𝑐⟩~
𝑛𝑐
𝑛𝐹𝑐
∑ 𝑝𝑔𝐹𝑔
𝑔
 
Let 𝛼𝑔 > 0 and 1 − 𝛼𝑔 be the relative proportions of somatic and germinal alteration of a particular 
genotype variant 𝑔 found in cancer individuals. I.e. 𝛼𝑐⟨𝑛𝑐⟩ patients are expected to acquire the alteration 
𝑐 somatically. The expected number of patients 𝑛𝑐
′  with somatic mutation 𝑐 is  〈𝑛𝑐
′ 〉 = 𝛼𝑐⟨𝑛𝑐⟩. When non-
somatic alteration are filtered out from the data, penetrance of gene 𝑐 is underestimated in the same 
proportion 
𝑝𝑐
′ = 𝛼𝑐𝑝𝑐 
Single locus: Let 𝐴 and 𝑎 be normal and malign allele’s variants at locus𝐴. Let 𝑃𝐴 and 𝑃𝑎 = 1 − 𝑃𝐴 be the 
probability that the normal and malign allele came up from the germline.  
Interactions: Let consider two interacting locus A and B with normal and malign variant allele’s A|a and 
B|b respectively, and 𝛼 and 𝛽 be each the relative proportions of somatic and germinal alterations in 
either locus respectively. When both malign alteration 𝑎 and 𝑏 co-occur in a patient, the chance this 
interacting variant a-b is counted by the somatic filtering is  
𝑃𝐴𝛼𝑃𝐵𝛽, 
that is the chance both malignant alterations were somatically acquired. The chance this interacting is 
undercounted is 
𝑃𝑎(1 − 𝛼)𝑃𝐵𝛽 + 𝑃𝐴𝛼𝑃𝑏(1 − 𝛽) + 𝑃𝑎(1 − 𝛼)𝑃𝑏(1 − 𝛽), 
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that is the chance that at least one of the malignant variant being not somatically acquired, which equal 
the chance tumor variants 𝑎 and 𝑏 (acquired or not somatically) co-occur, minus the chance both were 
acquired somatically. 
[𝑃𝑎(1 − 𝛼) + 𝑃𝐴𝛼][𝑃𝑏(1 − 𝛽) + 𝑃𝐵𝛽] − 𝑃𝐴𝛼𝑃𝐵𝛽  
Non-malign variants A and B can co-occur somatically by chance with probability 𝑃𝑎𝛼𝑃𝑏𝛽 in a patient 
sample; hence they are reported by the filtering process. The competence of this false interaction hit is 
unfair in the filtering scenario which undercounts the actual a-b interactions. 
The issue is magnified for those tumors requiring the cooperation between more than two driver 
alterations. For example, the chance 𝑛-order interaction of driver genes is undercounted is  
∏ [𝑃𝑎𝑖(1 − 𝛼𝑖) + 𝑃𝐴𝑖𝛼𝑖]
𝑛
𝑖∈loci
− ∏ 𝑃𝐴𝑖𝛼𝑖
𝑛
𝑖∈loci
 
Where 𝐴𝑖|𝑎𝑖  are the normal and malign variant allele’s of locus 𝑖 and 𝛼𝑖 is the relative proportions of 
somatic alteration in locus 𝑖, for 𝑛 interacting locus. 
Results and Discussion 
The filtering process leading to available somatic mutation data from TCGA confined to SNV for easy 
illustration is sketched in Table 1. In this hypothetical data sample suppose that variant 𝐶 is a malignant 
predisposing alteration in a given position of gene1. Since this variant appear somatically only in partient1, 
the same malign variant is not counted for patient2, which is carried un-mutated from the germline. 
Table 1: A sketch of the filtering process leading to available somatic data. The symbol “>” indicates the occurrence of a somatic 
mutation in a given gene position (orange background). For example G > C denotes a germline variant G mutated somatically to 
variant C in a given position of gene1 in patient 1. A single symbol (nucleotide) represent un-mutated germline variant, which 
are not reported (while background). 
 
gene1 gene2 gene3 gene4 gene5 gene5 
patient1 G > C A > T A > G A T > G T 
patient2 C A > T G A > C T A 
       
In general, those positions of a genome which are not somatically mutated are undercounted. These 
omission might have not relevant implications provided the relative frequency of the malign variant in the 
population can be dismissed with respect to those appearing somatically (i.e. 𝛼~1, as would be the 
commonest cases), ex. tumor suppressor gene TP53 exhibit a comparatively larger rate of somatic 
mutations (Kanchi et al., 2014). However, inherited alteration with relatively small somatic mutation 𝛼, 
rarely differ from the matched germinal line and are typically filtered out. For example malign variants of 
BRCA1 and BRCA2 genes are twice more frequently inherited than somatically acquired (Kanchi et al., 
2014). These malign variant found recurrently in breast and ovarian cancer germlines, are undoubtedly 
undercounted in the filtered data of somatic mutations, and current renowned software tools reflect the 
issue.  
The somatic filtering (undercounting) occur with probability 𝑃𝑎(1 − 𝛼), that is the chance of having the 
malign allele 𝑎, being it not somatically acquired. On the other hand, non-malign variant A can co-occur 
somatically with probability 𝑃𝑎𝛼 in individuals, hence they are reported by the filtering process. This false 
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hit can introduce a nuisance competence in the filtering scenario which undercount the actual 𝑎 variant. 
The undercounting of single alteration is detailed in Table 2. 
 
Table 2 
alterations probability True count Actual count True value Bias 
A > a 𝑃𝐴𝛼 +1 +1 TP No 
a 𝑃𝑎(1 − 𝛼) +1 0 FN Yes 
a > A 𝑃𝑎𝛼 +1 +1 FP Yes 
A 𝑃𝐴(1 − 𝛼) 0 0 TN No 
 expected 𝛼 + 𝑃𝑎(1 − 𝛼) 𝛼   
 
For example, a recent study of ovarian cancer (Supplementary Table 3, in Kanchi et al., 2014), BRCA1 
alterations were found in 71 of 429 cases, 50 of them were classified as germline alterations, and 21 as 
somatic mutations. By draft estimation we assign  
𝑃𝑎 =
21 + 50
429
,   𝛼 =
21
21 + 50
,    
The relative bias  
𝑃𝑎(1 − 𝛼)
𝛼 + 𝑃𝑎(1 − 𝛼)
= 0.282666 
Relative bias indicated that about 28% on average of the actual alteration hits are lost by the somatic 
filtering procedure. Similarly, BRCA2 alterations were found in 47 of 429 cases, 36 of them were classified 
as germline alterations, and 11 as somatic mutations. The same estimation above yields that 26% of the 
malignant alterations hits are filtered out.   
 The way somatic mutations data is made available imply that the set of locus whose variants are reported 
for one individual are not the same set of locus reported for other individual. The variant of a missing 
locus can then be implicitly regarded as a variant different to those alterations found somatically in the 
sample, since the count is not increased by neither of them.  
Let us consider the extremal case of an alteration 𝑐 with high penetrance and very low rate of somatic 
incidence i.e.  𝛼~0. If only somatic mutation are considered from the data, the chance to report this 
predominantly hereditary alteration in patients samples becomes very low 〈𝑛𝑐
′ 〉~0, even if ⟨𝑛𝑐⟩ were not 
small. In the most lucky case when0 ≪ 𝑛𝑐
′ , the penetrance estimation is underestimated, and association 
with driving mechanism are mostly biased. Further, as this high penetrance mutation passed unnoticed 
(false negative), even when it probably was the single alteration driving cell to cancer, the guilt is forcedly 
spread to other somatic alterations with sufficient counting statistic to cover the missed cause (false 
positive). This is not an unrealistic case, considering that 39 of 592 alterations reported in the cancer gene 
census are inherit alterations. Things can turned worse when gene interactions are examined. Let consider 
two locus A and B with variant allele’s a|A and b|B respectively. Population frequencies and penetrance 
are as follow: 
Let 𝛼 and 𝛽 be the proportion of somatic mutation in locus A and B respectively.   
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 Tumor variants pairs 
germline 
variants pair  
ab aB Ab AB 
ab 𝑃𝑎(1 − 𝛼)𝑃𝑏(1 − 𝛽) 𝑃𝑎(1 − 𝛼)𝑃𝑏𝛽 𝑃𝑎𝛼𝑃𝑏(1 − 𝛽) 𝑃𝑎𝛼𝑃𝑏𝛽 
aB 𝑃𝑎(1 − 𝛼)𝑃𝐵𝛽 𝑃𝑎(1 − 𝛼)𝑃𝐵(1 − 𝛽) 𝑃𝑎𝛼𝑃𝐵𝛽 𝑃𝑎(1 − 𝛼)𝑃𝑏𝛽 
Ab 𝑃𝐴𝛼𝑃𝑏(1 − 𝛽) 𝑃𝐴𝛼𝑃𝑏𝛽 𝑃𝐴(𝛼 − 1)𝑃𝑏(1 − 𝛽) 𝑃𝐴(1 − 𝛼)𝑃𝑏𝛽 
AB 𝑃𝐴𝛼𝑃𝐵𝛽 𝑃𝐴𝛼𝑃𝐵(1 − 𝛽) 𝑃𝐴(1 − 𝛼)𝑃𝐵𝛽 𝑃𝐴(1 − 𝛼)𝑃𝐵(1 − 𝛽) 
 
 Tumor variants pairs 
germline 
variants pair  
ab aB Ab AB 
ab 0 0 0 1 
aB 0 0 1 0 
Ab 0 1 0 0 
AB 1 0 0 0 
The interaction undercounting bias occur with probability 
𝑃𝑎(1 − 𝛼)𝑃𝑏(1 − 𝛽) + 𝑃𝑎(1 − 𝛼)𝑃𝐵𝛽 + 𝑃𝐴𝛼𝑃𝑏(1 − 𝛽) 
Importantly, inherited alterations with small somatic mutation rate rarely differ from the matched 
germinal line sample and are typically filtered out. Highly penetrant driver alterations can pass unnoticed 
by this procedure. Furthermore, significant interactions can be missed (false negative) and those counting 
statistics can amount for association between innocuous variant pairs (false positive interactions).  
The use of unfiltered germline data implies the analysis of huge volumes of information and its handling 
require granted access to controlled data (Jones et al., 2015). However, ignoring germline mutations 
underestimates the actual frequency of pathogenic alterations, and consequently overestimates non-
pathogenic frequency in patient samples. Furthermore, the filtering bias might impact the prediction of 
cancer drivers and mutually exclusive alterations, as well as the survival analysis performed by current 
analysis tools.  
For instance, IntOGen collects and analyses somatic mutations in thousands of tumor genomes to identify 
cancer driver genes by mutation frequency and signals of positive selection on protein-coding genes 
(Gonzalez-perez et al., 2013). However, by looking only in tumor somatic data the tool may be ignoring 
roughly twice the BRCA1/BRCA2 mutations that are actually reported (Kanchi et al., 2014). This bias may 
also significantly impact at least two major outputs from cBioPortal (Gao et al., 2014). Mutually Exclusive 
alterations and Survival analysis may be influenced when genes which are mutated at both germline and 
somatic level are included in the analysis. Of note, the Cancer Gene Census comprises roughly 97 of 595 
genes with germline mutations and 58 of them mutated at both levels (Futreal et al., 2004). Altogether, 
biased analysis are expected to be related to the frequency of rare pathogenic germline truncations 
underlying each tumor localization, from a mild anticipated impact on AML (roughly 4% of pathogenic 
germline truncations) to a potentially broader effect in ovarian cancer analysis (19%) (Lu et al., 2015). 
Remarkable, recent woks start to take into consideration full mutational patient data to analyze clinical 
significance of individual gene alterations and the potential interactions derived thereof (Kanchi et al., 
2014; Lu et al., 2015).  
Conclusion 
Malignant inherited alterations circulating in the population can be elusive to detection, analysis and 
clinical interpretation when genomic data is limited to filtered somatic alterations. Furthermore, 
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significant interactions between inherited and somatically acquired alterations may also being overlooked 
in cancer patients. Here, we estimated the bias introduced in common cancer genome analysis when 
mutational data is restricted to somatic alterations, and illustrated the potential implications of ignoring 
germline sequence data from normal-matched samples with well-known examples. Taking into account 
the growing list of identified pathogenic germline variants, tumor genome and germline sequence data is 
required to approach a more complete picture of the overall genetic foundation of the disease. 
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